Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Indian Herceptin Biosimilars Case Simmers

Executive Summary

The hotly contested case concerning biosimilar versions of Roche's Herceptin (trastuzumab) witnessed a seesaw shift after a division bench of the Delhi High Court held that the status prevailing prior to a stinging April 25 order against Biocon Ltd. and Mylan NV will continue to operate.

Advertisement

Related Content

Roche Fears 'Real' Biosimilar Competition Says Russia's Biocad
Roche Backs Off Mircera Suit In India
Indian Avastin Versions Head For Debut; Watch Off-Label Space
Court: No Herceptin Biosimilar Tag For Indian Trastuzumabs

Topics

Advertisement
UsernamePublicRestriction

Register

SC065080

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel